甲状腺癌的分子靶向治疗研究进展  

Advances in molecular targeted therapy of thyroid carcinoma

作　　者：冯辉豪 程晓明[1] 曾峰[1] 孔凡立[1] 赵洪远[1] 方小玉[1] 罗迤 

机构地区：[1]遵义医学院附属医院甲乳外科,贵州遵义563000

出　　处：《临床耳鼻咽喉头颈外科杂志》2015年第24期2188-2190,共3页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

摘　　要：1概述甲状腺癌是最常见的内分泌系统恶性肿瘤,约占人类所有恶性肿瘤发病率的1%~〔1-3〕。甲状腺乳头状癌和甲状腺滤泡状癌属于分化型甲状腺癌,是最常见的甲状腺癌类型,约占90%~〔4-5〕。手术治疗、131碘放射治疗、TSH抑制治疗是有效可靠的治疗方式~〔1,6-8〕,而系统性化疗方案不敏感。但仍有部分类型甲状腺癌无法获得可靠疗效及发生远处转移,其中包括手术无法完整切除的甲状腺癌病灶。Thyroid carcinoma is the most common endocrine maligancy,and the worldwide incidence has been rising in recent years.Differentiated thyroid carcinoma is the most common thyroid malignancy,which include thyroid papillary carcinoma and follicular thyroid carcinoma,accounting for about 90 percent of thyroid carcinoma incidence.Currently,surgical treatment,iodine radiotherapy and TSH suppressive therapy are the commonly accepted effective treatments for differentiated thyroid carcinoma,and most patients can be cured.But there are still some patients not sensitive to the general treatments,who have lost the treatment of opportunity.Molecular targeted therapy is an agonistic or suppressive treatment for molecular biology targets of malignant tumor,and currently is a frontier research in the field of malignancy treatment.By retrieving and analyzing the related literature of molecular targeted therapy of thyroid carcinoma through PUBMED in the past 5 years,the article introduced the current status of molecular targeted therapy of thyroid carcinoma.

关 键 词：甲状腺肿瘤 分子治疗 靶向治疗 

分 类 号：R736.1[医药卫生—肿瘤]